LICENSING & PARTNERING
Different Objectives. Different Access Models.
Pharmact structures D016 material supply, technology licensing, pharmaceutical development partnerships and strategic transactions as separate engagement models.
Separate legal and commercial models · no implied rights
ACCESS MODELS
Access to D016 material does not grant rights to the underlying technology, intellectual property or therapeutic development programs.
Supply provides access to defined D016 material under agreed specifications, quality requirements and commercial terms.
No technology license. No transfer of IP ownership.A license grants specifically defined rights to use Pharmact technology or intellectual property within an agreed field, territory, application or development program.
Rights are limited to the agreed scope. Ownership remains with the respective IP owner unless expressly transferred.Ownership means an assignment or transfer of defined intellectual-property rights or assets and is fundamentally different from supply or licensing.
No ownership transfer is implied by material supply, technical disclosure, development cooperation or licensing discussions.PARTNERING MODELS
The appropriate model depends on intended use, development stage, required rights, regulatory context, geography and the level of technical access.
Defined material supply for research, evaluation, industrial, cosmetic or other agreed B2B contexts under application-specific specifications and documentation.
Defined material · defined specification · defined use contextLicensing discussions may cover defined fields of use, territories, applications, development rights or commercialization rights, subject to technical, legal and commercial due diligence.
Rights only within the expressly agreed scopeBELACT partnering is distinct from D016 material supply and non-pharmaceutical licensing. Potential structures may include co-development, regional development rights, licensing, strategic investment or later-stage pharmaceutical partnering.
BELACT remains investigational; partnering does not imply clinical efficacy or regulatory approval.Pharmact may evaluate broader strategic structures where they are aligned with asset development, IP protection and long-term value creation.
Asset, program, regional-rights or other strategic structures require separate agreement.STRUCTURED PARTNER QUALIFICATION
Before detailed disclosure or supply, Pharmact may require information regarding intended use, technical capabilities, regulatory context, quality requirements, geographic scope and commercial objectives.
The exact sequence and level of review depend on the engagement model and required access.
RIGHTS / ACCESS MATRIX
The matrix illustrates the separation of common engagement models. Final rights, disclosure scope and commercial terms are governed only by the applicable executed agreement.
| Engagement | Material Access | Technical Information | Right to Use IP | Exclusive Rights | IP / Asset Ownership |
|---|---|---|---|---|---|
| Evaluation / Research Supply | Yes | Limited | No | No | No |
| Commercial Supply | Yes | Defined for supply and use | No | Only if expressly agreed; no implied IP exclusivity | No |
| Technology License | As agreed | Defined within licensed scope | Yes – within licensed scope | Possible if expressly agreed | No |
| Co-Development | As agreed | Project-specific | Defined by agreement | Possible | No, unless separately agreed |
| IP / Asset Transfer | As agreed | Agreed transaction scope | Transferred or assigned rights | As agreed | Possible – only if expressly transferred |
Rights and disclosures are defined by agreement – not inferred from access to material or information.
Material supply, technical discussions or access to documentation do not by themselves grant licensing, exclusivity, sub-licensing or ownership rights.
CONTROLLED DISCLOSURE
Technical Information Is Shared According to Project Scope.
Access does not automatically include:
Pharmact provides technical information at the level required for the qualified purpose of the engagement. Detailed proprietary information relating to expression, purification, manufacturing processes, analytical methods or other protected know-how may require confidentiality, technical qualification and an appropriate contractual framework.
The level of disclosure may increase as a project progresses from evaluation to licensing, co-development or another defined strategic structure.
U.S. DEVELOPMENT & PARTNERING
U.S.-related development and partnering structures may involve Pantarhin Pharma LLC within a defined project, rights and regulatory framework.
Involvement of a U.S. company does not by itself grant licensing, exclusivity, development or ownership rights.
VISIT PANTARHIN.COM →DEFINE THE RIGHT PARTNERING STRUCTURE
The appropriate structure depends on intended use, development stage, regulatory context, geography, required rights and the level of technical access.